Get the Stockscreener App
0.52
4.15%
-0.0225
After Hours:
.52
Evogene Ltd stock is traded at $0.52, with a volume of 95,104.
It is down -4.15% in the last 24 hours and up +33.71% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
See More
Previous Close:
$0.5425
Open:
$0.54
24h Volume:
95,104
Relative Volume:
0.06
Market Cap:
$6.29M
Revenue:
$1.84M
Net Income/Loss:
$-17.51M
P/E Ratio:
-0.3755
EPS:
-1.3849
Net Cash Flow:
$-17.30M
1W Performance:
-5.35%
1M Performance:
+33.71%
6M Performance:
-51.76%
1Y Performance:
-60.31%
1-Day Range:
$0.5081
$0.5539
1-Week Range:
$0.5081
$0.577
52-Week Range:
$0.37
$1.50
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.52 | 6.57M | 1.84M | -17.51M | -17.30M | -1.3849 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Form 13D/A Evogene Ltd. For: 27 July By Investing.com - Investing.com Canada
Evogene Ltd. (EVGN) holders report 17.41% stake and new ADS buys - Stock Titan
EVGN|Evogene Ltd|Price:0.542|Chg%:-0.006 - TradingKey
AI is rewiring future of energy cropsOfer Haviv, CEO, Evogene (EVGN) - AgroSpectrum India
Evogene and ELEO join forces to develop next-gen oral PCSK9 drugs targeting billion-dollar cardio market - Indian Pharma Post
Evogene Ltd (EVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Evogene Ltd. (EVGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Evogene Ltd (EVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evogene and ELEO to develop new oral PCSK9 inhibitors - Pharmaceutical Business review -
Evogene Ltd. (EVGN) stock price, news, quote and history - Yahoo Finance UK
Evogene and Eleo collaborate to discover PCSK9 pathway inhibitors - BioWorld News
Evogene (EVGN) Q1 2026 Earnings: Wider-than-Expected Loss Amid Ongoing R&D InvestmentsEarnings Analysis - dars.gov.et
Evogene and ELEO partner on oral PCSK9 inhibitor development By Investing.com - Investing.com South Africa
Evogene & ELEO Partner on Oral PCSK9 Inhibitors - AllSci
Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors - Moomoo
Evogene and ELEO partner on oral PCSK9 inhibitor development - Investing.com
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases - PR Newswire
Evogene stock trades quietly as genomics group leans on cash and recent revenue growth - Ad-hoc-news.de
Evogene (EVGN) investors add 202K ADSs, now hold 16.81% stake - Stock Titan
Evogene Expands ATM Offering as Shareholder Activism Escalates - TipRanks
EVGN (Nasdaq: EVGN) raises at-the-market ordinary share offering to $3.29M - Stock Titan
Activist investors target Evogene (NASDAQ: EVGN) board as ATM capacity rises - Stock Titan
AgPlenus Launches Antifungal Potency Predictor, Expanding ChemPass AI for Ag Capabilities - iGrow News
AgPlenus launches AI model to predict antifungal potency By Investing.com - Investing.com Nigeria
AgPlenus launches AI model to predict antifungal potency - Investing.com
AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities - Nasdaq
Evogene (EVGN) Edges Higher: Testing Key Resistance Amid Volume ShiftDefined Outcome ETF - dars.gov.et
EVGN Q1 2026 Earnings: EPS Misses Estimates by Wide Margin as Pre-Revenue Biotech Advances PlatformSpecial Dividend Alert - Bölüm Sonu Canavarı
Kfir Silberman Pushes for Board Changes at Evogene with 12.61% Stake - TradingView
Evogene (EVGN) investors with 12.61% and 4.13% stakes seek major board changes - Stock Titan
Evogene and Tel Aviv University launch drug discovery initiative - Pharmaceutical Business review -
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery - Global Agriculture
Evogene and Tel Aviv University team up to speed small-molecule drug discovery - Stock Titan
Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery - marketscreener.com
Evogene Partners with Tel Aviv University on AI Drug... - AllSci
Evogene and Tel Aviv University to accelerate AI-driven small-molecule drug discovery - BioSpectrum Asia
Evogene partners with Tel Aviv University center on drug discovery - Investing.com
Evogene partners with Tel Aviv University center on drug discovery By Investing.com - Investing.com India
Evogene Ltd (EVGN) Edges Higher Amid Consolidation, Testing Key Resistance at $0.46Double EMA - dars.gov.et
How Evogene is changing the future for the pharma and agriculture markets - The Jerusalem Post
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Evogene (EVGN) Q1 2026 Earnings: EPS Misses Estimates Sharply as Revenue Remains AbsentEarnings Risk Report - dars.gov.et
Evogene | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Price to book forward of Evogene Ltd. – NASDAQ:EVGN - TradingView
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):